DEPACON

Clinical safety rating: caution

Comprehensive clinical and safety monograph for DEPACON (DEPACON).

How it works

Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels.

What the body does with it

Metabolism	Metabolized primarily via glucuronidation (CYP-independent) and beta-oxidation; less than 3% excreted unchanged in urine.
Excretion	Primarily renal: >90% of a dose is excreted in urine as valproic acid glucuronide (30–50%), 3-oxo-valproic acid (30–40%), and other metabolites. Less than 3% excreted unchanged. Minor fecal elimination (≈5%).
Half-life	10–16 hours; neonates 20–30 hours; patients with liver disease up to 18 hours; decreased half-life in patients on enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine) to 4–9 hours.
Protein binding	90–95% bound to albumin; binding is saturable and decreased in uremia, hypoalbuminemia, and in elderly patients.
Volume of Distribution	0.13–0.23 L/kg; increases with age and obesity; small Vd indicates predominant distribution in plasma and extracellular fluid.
Bioavailability	Oral (immediate-release): ~100%; IV: 100%; rectal administration (not standard): approximately 80%.
Onset of Action	Oral (immediate-release): 3–5 days for maximal seizure control; IV loading dose produces therapeutic levels within minutes, with clinical effect within 1–2 hours.
Duration of Action	Approximately 8–12 hours for immediate-release oral and IV formulations; sustained-release formulations provide therapeutic effects for 24 hours.

Classification & Brands

Dosing & administration

10-15 mg/kg/day IV or orally divided every 8 hours; maximum 60 mg/kg/day.

Dosage form	INJECTABLE
Renal impairment	GFR 30-60 mL/min: reduce dose by 30%; GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: avoid use or reduce dose by 70%.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 30%; Child-Pugh C: reduce dose by 50%.
Pediatric use	10-20 mg/kg/day IV or orally divided every 6-8 hours; maximum 40 mg/kg/day.
Geriatric use	Start at lowest dose (10 mg/kg/day) and titrate slowly; monitor renal function and adjust accordingly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for DEPACON (DEPACON).

Breastfeeding	Valproate is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.05-0.1. Infant serum levels are low (1-10% of maternal levels). The American Academy of Pediatrics considers it compatible with breastfeeding. However, monitor for potential adverse effects such as hepatic dysfunction or thrombocytopenia in the infant.
Teratogenic Risk	Valproate (Depacon) is highly teratogenic. First trimester exposure is associated with a 3-4% risk of neural tube defects (spina bifida), as well as craniofacial defects, cardiac defects, and hypospadias. Second and third trimester exposure may be linked to neurodevelopmental disorders including autism spectrum disorder and low IQ. Risk is dose-dependent.

Warnings & precautions

■ FDA Black Box Warning

Hepatotoxicity: Cases of life-threatening hepatic failure, especially in children under 2 years and patients with mitochondrial disease; fatalities reported. Contraindicated in patients with known liver disease.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to valproate","Active liver disease or hepatic dysfunction","Urea cycle disorders","Women of childbearing potential (unless alternative treatments ineffective or benefits outweigh risks)"]

Clinical Precautions

Precautions

["Hepatotoxicity: Monitor liver function tests before and during therapy; discontinue if significant elevation.","Pancreatitis: Rare but potentially fatal; discontinue if pancreatitis suspected.","Hyperammonemic encephalopathy: Often in patients with urea cycle disorders or concomitant medications; monitor ammonia levels.","Teratogenicity: Valproate exposure causes neural tube defects and neurodevelopmental disorders; avoid in women of childbearing potential unless ineffective alternatives.","Thrombocytopenia and coagulation disorders: Platelet count and bleeding time monitoring recommended."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

DEPACON

Clinical safety rating: caution

Comprehensive clinical and safety monograph for DEPACON (DEPACON).

How it works

Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels.

What the body does with it

Metabolism	Metabolized primarily via glucuronidation (CYP-independent) and beta-oxidation; less than 3% excreted unchanged in urine.
Excretion	Primarily renal: >90% of a dose is excreted in urine as valproic acid glucuronide (30–50%), 3-oxo-valproic acid (30–40%), and other metabolites. Less than 3% excreted unchanged. Minor fecal elimination (≈5%).
Half-life	10–16 hours; neonates 20–30 hours; patients with liver disease up to 18 hours; decreased half-life in patients on enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine) to 4–9 hours.
Protein binding	90–95% bound to albumin; binding is saturable and decreased in uremia, hypoalbuminemia, and in elderly patients.
Volume of Distribution	0.13–0.23 L/kg; increases with age and obesity; small Vd indicates predominant distribution in plasma and extracellular fluid.
Bioavailability	Oral (immediate-release): ~100%; IV: 100%; rectal administration (not standard): approximately 80%.
Onset of Action	Oral (immediate-release): 3–5 days for maximal seizure control; IV loading dose produces therapeutic levels within minutes, with clinical effect within 1–2 hours.
Duration of Action	Approximately 8–12 hours for immediate-release oral and IV formulations; sustained-release formulations provide therapeutic effects for 24 hours.

Classification & Brands

Dosing & administration

10-15 mg/kg/day IV or orally divided every 8 hours; maximum 60 mg/kg/day.

Dosage form	INJECTABLE
Renal impairment	GFR 30-60 mL/min: reduce dose by 30%; GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: avoid use or reduce dose by 70%.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 30%; Child-Pugh C: reduce dose by 50%.
Pediatric use	10-20 mg/kg/day IV or orally divided every 6-8 hours; maximum 40 mg/kg/day.
Geriatric use	Start at lowest dose (10 mg/kg/day) and titrate slowly; monitor renal function and adjust accordingly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for DEPACON (DEPACON).

Breastfeeding	Valproate is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.05-0.1. Infant serum levels are low (1-10% of maternal levels). The American Academy of Pediatrics considers it compatible with breastfeeding. However, monitor for potential adverse effects such as hepatic dysfunction or thrombocytopenia in the infant.
Teratogenic Risk	Valproate (Depacon) is highly teratogenic. First trimester exposure is associated with a 3-4% risk of neural tube defects (spina bifida), as well as craniofacial defects, cardiac defects, and hypospadias. Second and third trimester exposure may be linked to neurodevelopmental disorders including autism spectrum disorder and low IQ. Risk is dose-dependent.